Alzheimer’s: A treatment shows promise in slowing the disease’s destruction of the human brain

  • James Gallagher
  • Health and science journalist

news/240/cpsprodpb/14426/production/_127828928_2022-11-29224548.jpg.webp 240w, 320w, 480w, 624w, 800w" type="image/webp" sizes="(min-width: 1008px) 645px, 100vw"/>news/240/cpsprodpb/14426/production/_127828928_2022-11-29224548.jpg 240w, 320w, 480w, 624w, 800w" type="image/jpeg" sizes="(min-width: 1008px) 645px, 100vw"/>

image copyright Getty Images

photo comment,

Licanib is an antibody designed to tell the immune system to clear amyloid from the brain

The announcement of the first drug effective in slowing brain damage resulting from dementia (Alzheimer’s disease) was highly celebrated by the medical community, which considered it an historic and important moment.

This research breakthrough is set to end decades of failure and demonstrate that a new era of drugs is possible to treat Alzheimer’s disease, the most common form of dementia.

Despite this, the drug, called lecanimab, has only a small effect and its impact on people’s daily lives is still a matter of debate.

The drug works in the early stages of the disease, so most patients won’t benefit from the new discovery unless methods of early detection are developed.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Recent News

Editor's Pick